Marie D Ralff Selected Research

TIC10 compound

12/2021	Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo.
12/2021	Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
10/2020	TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.
1/2018	Role of Dopamine Receptors in the Anticancer Activity of ONC201.
1/2018	ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
1/2018	Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
10/2017	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.
10/2017	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
10/2017	ONC201: a new treatment option being tested clinically for recurrent glioblastoma.
1/2017	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marie D Ralff Research Topics

Disease

13	Neoplasms (Cancer) 01/2022 - 01/2017
2	Pancreatic Neoplasms (Pancreatic Cancer) 12/2021 - 10/2017
2	Breast Neoplasms (Breast Cancer) 10/2020 - 01/2017
2	Triple Negative Breast Neoplasms 10/2020 - 01/2017
2	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 10/2017
2	Melanoma (Melanoma, Malignant) 10/2017 - 10/2017
2	Glioblastoma (Glioblastoma Multiforme) 10/2017 - 01/2017
1	Endometrial Neoplasms (Endometrial Cancer) 12/2021
1	Neoplasm Metastasis (Metastasis) 01/2018
1	Liver Neoplasms (Liver Cancer) 10/2017
1	Skin Neoplasms (Skin Cancer) 10/2017
1	Colorectal Neoplasms (Colorectal Cancer) 01/2017

Drug/Important Bio-Agent (IBA)

11	TIC10 compoundIBA 12/2021 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2017
2	TNF-Related Apoptosis-Inducing LigandIBA 01/2018 - 01/2017
2	ONC212IBA 10/2017 - 10/2017
1	InterferonsIBA 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2022
1	Caspase 3 (Caspase-3)IBA 12/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2018
1	Hormones (Hormone)IBA 01/2018
1	Androgen Receptors (Androgen Receptor)IBA 01/2018
1	Docetaxel (Taxotere)FDA Link 01/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018
1	Everolimus FDA Link 01/2018
1	enzalutamideIBA 01/2018
1	AndrogensIBA 01/2018
1	Fluorouracil (Carac)FDA LinkGeneric 10/2017
1	Endoplasmic Reticulum Chaperone BiPIBA 10/2017
1	CrizotinibIBA 10/2017
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2017
1	Irinotecan (Camptosar)FDA LinkGeneric 10/2017
1	tyrphostin AG 1024IBA 10/2017
1	ONC206IBA 10/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	RNA (Ribonucleic Acid)IBA 01/2017

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2017
1	Castration 01/2018